Slide 1: Corporate Presentation
Corporate Presentation December 15, 2021 © 2021 Nicox. All rights reserved
Slide 2: Forward-Looking Statements
Forward-Looking Statements This document has been prepared by Nicox SA and may not be reproduced or distributed, in whole or in part. The information contained in this document has not been independently verified and no representation, warranty or undertaking, expressed or implied, is made as to, an
Slide 3: Nicox: A Unique Profile for an R&D Company
Nicox: A Unique Profile for an R&D Company Euronext Paris: COX Potential best-in-class intraocular pressure lowering treatment for patients with glaucoma in two Phase 3 trials in U.S. and China Novel ocular surface disease treatment – blepharitis Phase 2b trial completed – U.S. FDA meeting in early
Slide 4: Pipeline
Pipeline Stages of Development Expected Preclinical Phase 1 Phase 2 Phase 3 NDA Marketed milestones NO-Donating Product Candidates Targeting Glaucoma Top-line results: NCX 470 | novel NO-donating prostaglandin analog Mont Blanc and Denali trials - Mont Blanc Q1 2023 Partnered with Ocumension in the
Slide 5: NCX 470: Novel Late-Stage Product Candidate in Glaucoma
NCX 470: Novel Late-Stage Product Candidate in Glaucoma Based on Nicox’s NO-Donating Research Platform 5
Slide 6: Glaucoma Results in Progressive and Irreversible Vision Loss
Glaucoma Results in Progressive and Irreversible Vision Loss Normal Reduced aqueous aqueous humor humor outflow outflow Healthy eye Intraocular Pressure (IOP) builds up Typical effect of glaucoma on vision ~3 million patients in the U.S. with open angle glaucoma1 Unmet medical need: 40% of patients
Slide 7: NCX 470 Targets ~$1.4 Billion U.S. Glaucoma PGA Market
NCX 470 Targets ~$1.4 Billion U.S. Glaucoma PGA Market1 U.S. Glaucoma Pharmaceuticals Market is ~50% of the Global Market1 PGA Prescription Volume2 PGA Prescription Value3 TRAVATAN Z VYZULTA LUMIGAN (bimatoprost) (travoprost) (latanoprostene 12% 9% bunod) TRAVATAN Z (travoprost) 4% 3% ROCKLATAN (net
Slide 8: NCX 470 Targets the Two Key Outflow Pathways for Lowering IOP
NCX 470 Targets the Two Key Outflow Pathways for Lowering IOP Potential for Best-in-Class Efficacy with Novel Dual Mechanism of Action Two pathways for aqueous humor outflow 8
Slide 9: NCX 470: Statistical Superiority to Market Leader in IOP lowering
NCX 470: Statistical Superiority to Market Leader in IOP lowering Linear Dose Response Suggests Potential Higher Efficacy for Phase 3 Dose Efficacy vs Side Effect Profile Summary Phase 2 Dolomites Trial Results Observed in Phase 2 Trial • Large Phase 2 trial achieved statistical superiority to marke
Slide 10: NCX 470: 2 Phase 3 trials Support U.S. & China NDA Submissions
NCX 470: 2 Phase 3 trials Support U.S. & China NDA Submissions Top-line Results Currently Expected in Q1 2023 and by end 2023 Randomized, double-masked in patients with open angle glaucoma or ocular hypertension Mont Blanc trial N=~670, across ~50 clinical sites in the U.S. and some sites in China.
Slide 11: NCX 470 Potential Peak Sales in U.S. First-Line Glaucoma Market
NCX 470 Potential Peak Sales in U.S. First-Line Glaucoma Market EXISTING MARKET: ~$1.4 billion1 NCX 470 Current Traditional2 PGAs VYZULTA (latanoprostene ROCKLATAN (netarsudil therapies bunod ophthalmic solution), and latanoprost ophthalmic NCX 470 potential Latanoprost: Latanoprost:>70% prescriptio
Slide 12: NCX 470 Shows Retinal Cell Protection in a Non-Clinical Model
NCX 470 Shows Retinal Cell Protection in a Non-Clinical Model1 Improved ocular perfusion and retinal function in damaged eyes Potential therapeutic properties beyond IOP lowering • Ophthalmic OcularArtery Retinal function1 Resistive Index changes ischemia/reperfusion hemodynamics (Echo-doppler - Oph
Slide 13: NCX 1728: Lead Compound in a New Class of IOP Lowering Agents
NCX 1728: Lead Compound in a New Class of IOP Lowering Agents Molecules in this new class showed robust IOP lowering in a non-human primate model of ocular hypertension1 • Lead in a new class of compounds (non-PGA related) with NO-mediated IOP lowering effects enhanced and prolonged by concomitant P
Slide 14: NCX 1741, an analog of NCX 1728, lowers IOP in ocular hypertensive non-human primates
NCX 1741, an analog of NCX 1728, lowers IOP in ocular hypertensive non-human primates1,2 NCX 1741, an analog of NCX 1728, has faster onset of action and similar IOP-lowering efficacy as travoprost for up to 8h post-dosing in ocular hypertensive non-human primates1,2 *p<0.05 vs. vehicle at the respec
Slide 15: NCX 4251: Novel Treatment to Address Unmet Medical Need in Ocular Surface Disease
NCX 4251: Novel Treatment to Address Unmet Medical Need in Ocular Surface Disease 15
Slide 16: Blepharitis - An Unmet Medical Need
Blepharitis - An Unmet Medical Need NCX 4251: A Potential Novel Therapy for a Chronic, Difficult to Treat Disease Prevalence No approved FDA treatments for acute exacerbations Eyelid hygiene Antibiotics Corticosteroid ointments Unique eyelid application to site of inflammation designed to 37- 47% mi
Slide 17: NCX 4251: Mississippi Phase 2b Clinical Trial and Next Steps
NCX 4251: Mississippi Phase 2b Clinical Trial and Next Steps Potential for future development in blepharitis or dry eye Design Mississippi was a U.S. Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension, 0.1%
Slide 18: NCX 4251: Efficacy in Reducing Signs & Symptoms of Blepharitis
NCX 4251: Efficacy in Reducing Signs & Symptoms of Blepharitis1 Data for Potential Future Development in Blepharitis Reduction from baseline in eyelid composite score1 Blepharitis Results (eyelid redness, eyelid discomfort and eyelid debris) • Numerical improvement over placebo in the primary outcom
Slide 19: NCX 4251: Efficacy in Reducing Signs & Symptoms of Dry Eye
NCX 4251: Efficacy in Reducing Signs & Symptoms of Dry Eye1 Post hoc analysis provides further data for FDA discussion in Dry Eye Reduction from baseline in eye dryness score2 Post hoc subset analysis in patients with inferior corneal fluorescein staining score of >=2 • 123 of the overall 224 patien
Slide 20: Corporate
Corporate • Key Partnerships • Financial Highlights • Anticipated Value-Creating Milestones 20
Slide 21: Key Commercial Partnerships
Key Commercial Partnerships VYZULTA ZERVIATE OCUMENSION PARTNERSHIP Partnered with Bausch + Lomb worldwide Partnered with Eyevance in the U.S. • First eye drop approved in 20 • First and only topical ophthalmic • Exclusive rights3 in China and years with a novel approach to formulation of cetirizine
Slide 22: Financial Highlights
Financial Highlights Estimated Financial Position as of December 31, 20211 Analyst Coverage Cash, Cash Equivalents €40.5 million Bryan Garnier Dylan Van Haaften Debt2 €18.3 million Cantor Fitzgerald Louise Chen Cash runway Q4 2023 H.C. Wainwright Yi Chen Kepler Cheuvreux Damien Choplain Edison Inves
Slide 23: Value-Creating Milestones
Value-Creating Milestones Building Our Late-Stage Ophthalmic Portfolio for Commercialization NCX 4251 Blepharitis NCX 4251 Blepharitis Phase 2b Mississippi U.S. FDA meeting trial completed early 2022 NCX 470 Glaucoma Phase 3 Mont Blanc NCX 470 Phase 3 Mont top-line results Blanc >70% enrollment Q1 2
Slide 24: Innovative Solutions to Help Maintain Vision and Improve Ocular Health
Innovative Solutions to Help Maintain Vision and Improve Ocular Health Nicox S.A. Nicox Ophthalmics, Inc. Nicox Research Institute S.r.l. Drakkar 2 – Bât. D 4721 Emperor Blvd. Suite 260 Via Ariosto 21 2405 Route des Dolines Durham, NC 27703, U.S. 20091 Bresso CS 10313 Sophia Antipolis Milano, Italy